[go: up one dir, main page]

WO2007053792A3 - Amelioration des proprietes pharmacocinetiques d'inhibiteurs de proteases et d'autres medicaments - Google Patents

Amelioration des proprietes pharmacocinetiques d'inhibiteurs de proteases et d'autres medicaments Download PDF

Info

Publication number
WO2007053792A3
WO2007053792A3 PCT/US2006/043400 US2006043400W WO2007053792A3 WO 2007053792 A3 WO2007053792 A3 WO 2007053792A3 US 2006043400 W US2006043400 W US 2006043400W WO 2007053792 A3 WO2007053792 A3 WO 2007053792A3
Authority
WO
WIPO (PCT)
Prior art keywords
host
pharmacokinetics
drugs
improving
pharmacokinetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/043400
Other languages
English (en)
Other versions
WO2007053792A2 (fr
Inventor
Mitchell W Mutz
Jason E Gestwicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amplyx Pharmaceuticals Inc
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of WO2007053792A2 publication Critical patent/WO2007053792A2/fr
Publication of WO2007053792A3 publication Critical patent/WO2007053792A3/fr
Priority to US12/151,329 priority Critical patent/US20080306098A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de modulation d'au moins une propriété pharmacocinétique d'un inhibiteur de protéase lors de son administration à un hôte. La méthode consiste à administrer à l'hôte une quantité efficace d'un composé bifonctionnel inférieur à environ 5000 daltons, comprenant l'inhibiteur de protéase ou un dérivé actif de celui-ci et un fragment de modulation pharmacocinétique. Le fragment de modulation pharmacocinétique est lié à au moins une protéine intracellulaire. Le composé bifonctionnel présente au moins une propriété pharmacocinétique modulée lors de son administration à l'hôte par rapport à un témoin de médicament libre comprenant l'inhibiteur de protéase.
PCT/US2006/043400 2005-11-05 2006-11-06 Amelioration des proprietes pharmacocinetiques d'inhibiteurs de proteases et d'autres medicaments Ceased WO2007053792A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/151,329 US20080306098A1 (en) 2006-11-06 2008-05-05 Pharmacokinetics of protease inhibitors and other drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73419705P 2005-11-05 2005-11-05
US60/734,197 2005-11-05

Publications (2)

Publication Number Publication Date
WO2007053792A2 WO2007053792A2 (fr) 2007-05-10
WO2007053792A3 true WO2007053792A3 (fr) 2007-11-15

Family

ID=38006529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043400 Ceased WO2007053792A2 (fr) 2005-11-05 2006-11-06 Amelioration des proprietes pharmacocinetiques d'inhibiteurs de proteases et d'autres medicaments

Country Status (1)

Country Link
WO (1) WO2007053792A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077317A2 (fr) * 2008-12-17 2010-07-08 Amplyx Pharmaceuticals, Inc. Inhibiteurs des protéases
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2015038649A1 (fr) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Thérapeutique ciblée
WO2015066053A2 (fr) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Thérapies ciblées
JP2017505777A (ja) 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
KR20160126078A (ko) 2014-03-03 2016-11-01 신타 파마슈티칼스 코프. 표적 치료제
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
AU2018289339A1 (en) 2017-06-20 2020-01-02 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
CN114591442B (zh) * 2022-03-01 2024-04-19 中国科学院深圳先进技术研究院 一种受光调控的蛋白酶工具及其配套底物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571698A (en) * 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US6921531B2 (en) * 1998-05-22 2005-07-26 The Board Of Trustees Of The Leland Stanford Junior University Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy
US20050176758A1 (en) * 1995-02-27 2005-08-11 Norbert W. Bischofberger Novel compounds and methods for synthesis and therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571698A (en) * 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US20050176758A1 (en) * 1995-02-27 2005-08-11 Norbert W. Bischofberger Novel compounds and methods for synthesis and therapy
US6921531B2 (en) * 1998-05-22 2005-07-26 The Board Of Trustees Of The Leland Stanford Junior University Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WELLING P. AND DOBRINSKA M.: "Dosing and Bioavailability. Controlled Drug Delivery: Fundamentals and Applications", vol. 2ND ED., 1978, MARCEL DEKKER, INC., NEW YORK *

Also Published As

Publication number Publication date
WO2007053792A2 (fr) 2007-05-10

Similar Documents

Publication Publication Date Title
WO2007053792A3 (fr) Amelioration des proprietes pharmacocinetiques d'inhibiteurs de proteases et d'autres medicaments
AU2003263599A1 (en) Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
EP1650192A4 (fr) Derive de quinolone ou sel de ce dernier
AU2000264559A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
CY2013023I1 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
WO2005034908A3 (fr) Forme posologique solide comprenant une fibrate et une statine
EP2204181A3 (fr) Inhibiteurs de protéase
AU2003276656A1 (en) Transdermal delivery system for anti-emetic medication
WO2005046662A3 (fr) Complexes pour une therapie combinatoire stimulant les hdl
WO2003080070A3 (fr) Combinaison de composés organiques
WO2007056205A3 (fr) Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles
EP1589947B8 (fr) Formulation pharmaceutique ayant un agent actif insoluble
EP1619180A4 (fr) ANTAGONISTE DE CaSR
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
WO2002089788A3 (fr) Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase
WO2007005941A3 (fr) Conjugues cibles sur le foie
WO2003024933A1 (fr) Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
EP1602645A4 (fr) Derive heterocyclique azote contenant du styryl 2,6-disubstitue
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2004071402A3 (fr) Forme pharmaceutique stable comprenant un inhibiteur de reductase hmg-coa
WO2008059502A3 (fr) Compositions pour verres de contact
WO1999057098A3 (fr) INHIBITEURS β-AMINO-ACIDE SUBSTITUES DE LA METHIONINE AMINOPEPTIDASE-2
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
WO2001014886A3 (fr) Inhibiteurs de liaison entre des proteines et des ligands macromoleculaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837104

Country of ref document: EP

Kind code of ref document: A2